Bio-Rad Laboratories (BIO) reported Q1 adjusted earnings late Thursday of $2.54 per diluted share, up from $2.30 a year earlier.

Analysts polled by FactSet expected $1.81.

Revenue for the quarter ended March 31 was $585.4 million, compared with $610.8 million a year earlier.

Analysts surveyed by FactSet expected $573.3 million.

The company said it now expects 2025 non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, compared with its prior revenue growth estimate of about 1.5% to 3.5%.